CDXSHealthcare · BiotechnologyThe 7 Wall Street analysts covering Codexis, Inc. hold a median 12-month price target of $7 — +348.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 70 of 100 as at 15 Aug 2026 — in the upper half. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Codexis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Volatility (8): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on CDXS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +348.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 22 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | $11 |
| 22 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 15 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | $11 |
| 15 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 4 Nov 2024 | Benchmark | Reiterates | Hold | — |
| 20 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 29 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 19 Aug 2024 | Benchmark | Downgrade | Hold | — |
| 9 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 30 May 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 3 May 2024 | Benchmark | Reiterates | Buy | — |
| 29 Feb 2024 | Benchmark | Upgrade | Buy | — |
| 7 Nov 2023 | Benchmark | Downgrade | Hold | — |
| 6 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 1 Sept 2023 | Benchmark | Reiterates | Buy | — |
| 14 Aug 2023 | Stifel | Maintains | Buy | — |
| 21 July 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 9 May 2023 | Benchmark | Maintains | Buy | — |
| 9 May 2023 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 17 Apr 2023 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CDXS appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 87% of US stocks
Cheaper than 51% of US stocks
Cheaper than 26% of US stocks
Cheaper than 84% of US stocks
Higher than 23% of US stocks
Higher than 85% of US stocks
Higher than 95% of US stocks
Higher than 15% of US stocks
Higher than 12% of US stocks
Higher than 17% of US stocks
Higher than 25% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Codexis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Codexis was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Why it matters — An upgrade to Buy suggests increased positive sentiment around Codexis's near-term earnings outlook, which could influence how investors view the stock.
Codexis, Inc. held its Q2 2026 earnings call, the transcript of which was published by Seeking Alpha. The call covered the company's financial results and operational highlights for the quarter.
Why it matters — Earnings call transcripts provide CDXS watchers with direct insight into management's commentary on quarterly performance and strategic direction.
Codexis reported a second-quarter loss of $0.13 per share, narrower than the Zacks Consensus Estimate of a $0.17 loss and an improvement from the $0.16 loss in the same period last year. The company also topped revenue estimates for the quarter.
Why it matters — A CDXS watcher would care because the company beat analyst expectations on both earnings and revenue, indicating better-than-anticipated quarterly performance.
Codexis reported second-quarter 2026 revenue of $14.9 million, down from $15.3 million in the prior-year period. The company highlighted improved performance in its biocatalytic enzyme business and continued development of its ECO Synthesis platform for siRNA manufacturing.
Why it matters — CDXS watchers would care because the results offer a snapshot of the company's core enzyme business and the progress of its ECO Synthesis platform, a key part of its growth strategy.
Codexis reported second quarter 2026 financial results with revenue of $14.9 million and reiterated its full-year financial guidance. The company also shared advances in RNA therapeutic manufacturing using its ECO Synthesis® Manufacturing Platform and completed an equity capital raise of approximately $25 million in net proceeds.
Why it matters — A CDXS watcher would care because the company reaffirmed its financial outlook and reported progress in its RNA therapeutic manufacturing technology, along with a completed equity raise that added about $25 million in net proceeds.
The 7 Wall Street analysts covering Codexis, Inc. have a median 12-month price target of $7, with estimates ranging from $2 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Codexis, Inc., 5 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Codexis, Inc. 70 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 15 Aug 2026, Codexis, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +348.7% from the last close, and Ticker Nerd's factor model ranks Codexis, Inc. 70 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Codexis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $11 over the next 12 months.
Codexis, Inc. returned -49.7% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Codexis Inc. is a leading enzyme engineering company that develops scalable, sustainable enzymatic solutions for therapeutic manufacturing and development.
The most recent item we track (Zacks Investment Research, 14 Aug 2026): "Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?". Codexis was upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.
Codexis Inc. is a leading enzyme engineering company that develops scalable, sustainable enzymatic solutions for therapeutic manufacturing and development. It leverages the proprietary CodeEvolver protein engineering technology platform to design and optimize novel enzymes that outperform traditional methods, enabling efficient production with fewer impurities, reduced waste, and lower energy use. The company operates through two main segments: Performance Enzymes, which commercializes enzyme products and technologies primarily for the pharmaceuticals market, including applications in RNAi therapeutics manufacturing via the ECO Synthesis platform; and Novel Biotherapeutics, which focuses on discovering and improving biotherapeutic drug candidates. Codexis Inc. also provides enzymes for precision diagnostics, such as Codex HiFi Hot Start DNA Polymerase and screening kits, along with services supporting small molecule manufacturing. These offerings serve partners in therapeutics development across regions including the United States, Europe, Asia, and beyond. Founded in 2002 and headquartered in Redwood City, California, Codexis Inc. plays a key role in advancing enzymatic manufacturing innovations for the biotechnology and pharmaceutical industries.
CEO Dr. Alison Moore Ph.D. · 146 employees · United States · https://www.codexis.com